| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/30/2003 | WO2002014536A3 Odulating multiple lineage kinase proteins |
| 01/30/2003 | WO2002010393A3 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 01/30/2003 | WO2002007773A3 Multi-component biological transport systems |
| 01/30/2003 | WO2002007765A3 REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE |
| 01/30/2003 | WO2002005795B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/30/2003 | WO2002004491A3 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2002000617A3 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/30/2003 | WO2001091792A9 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 01/30/2003 | WO2001091772A3 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | WO2001064877A9 Human schizophrenia gene |
| 01/30/2003 | US20030023997 Transgenic c. elegans as a model organism for investigations on alzheimer's disease |
| 01/30/2003 | US20030023993 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation |
| 01/30/2003 | US20030023990 Jnk3 modulators and methods of use |
| 01/30/2003 | US20030023283 Method and apparatus for the stimulation of hair growth |
| 01/30/2003 | US20030023038 For therapy of undesired cell proliferation; for stimulation and inhibition of lymphocytes |
| 01/30/2003 | US20030023034 p27 (Kip1) -FKBP-12 protein complexes |
| 01/30/2003 | US20030023033 Novel class II cytokine receptors and uses thereof |
| 01/30/2003 | US20030022944 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/30/2003 | US20030022926 Method for treating neuropathic pain and pharmaceutical preparation therefor |
| 01/30/2003 | US20030022923 Methods for treatment of sickle cell anemia |
| 01/30/2003 | US20030022918 (imidazoly-5-yl)methyl-2-quinolinone derivatives; antitumor agents |
| 01/30/2003 | US20030022915 Treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, and other psychological disorders |
| 01/30/2003 | US20030022912 Rapid-onset medicament for treatment of sexual dysfunction |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022906 Use of pde v inhibitors |
| 01/30/2003 | US20030022900 Compositions comprising alpha-1C specific compounds |
| 01/30/2003 | US20030022897 Use of cox-2 inhibitors as gastroprokinetics |
| 01/30/2003 | US20030022894 Imidazotriazinone-containing compositions for nasal administration |
| 01/30/2003 | US20030022891 Melanin-concentrating hormone (MCH); treating metabolic and eating disorders, such as hyperphagia, and diabetes; urea, thiourea and cyano-guanidine compounds of given formula |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022879 Via catheter comprising antimicrobial agent and second catheter for withdrawing fluid; for treating infection or neoplasm of cerebrospinal tissue |
| 01/30/2003 | US20030022875 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 01/30/2003 | US20030022870 Methods of treating cardiac disorders |
| 01/30/2003 | US20030022866 Analgesic inhibitor of isoforms of cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (PKGI alpha); drug screening |
| 01/30/2003 | US20030022860 CD40 binding molecules and CTL peptides for treating tumors |
| 01/30/2003 | US20030022855 Melanoma differentiation associated gene-5 (mda-5) nucleic acids, proteins, and gene promoters for induction of apoptotic cell death |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022822 Novel compounds |
| 01/30/2003 | US20030022819 Administering to an animal an angiogenic amount of a hedgehog polypeptide or agonist to promote angiogenesis |
| 01/30/2003 | US20030022818 Formulations of tocopherols and methods of making and using them |
| 01/30/2003 | US20030022814 Method for treating or preventing depression |
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022354 Protein c derivatives |
| 01/30/2003 | US20030022349 Virulence-associated nucleic acid sequences and uses thereof |
| 01/30/2003 | US20030022339 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/30/2003 | US20030022325 Nucleotide sequences coding transport protein for use in diagnosis and treatment of cancers, kidney, bone and nervous sysem disorders |
| 01/30/2003 | US20030022321 Novel compounds |
| 01/30/2003 | US20030022312 Human hepatoma-derived growth factor-2 |
| 01/30/2003 | US20030022283 Neuropeptide Y receptor Y5 and nucleic acid sequences |
| 01/30/2003 | US20030022275 Human nk-3 related prostate specific gene-1 |
| 01/30/2003 | US20030022241 Detection of modulators of enzyme activity; obtain sample containing kinase activity, incubate with modulator, monitor diabetic response |
| 01/30/2003 | US20030022238 Methods of identifying agents which inhibit GPR-9-6 |
| 01/30/2003 | US20030022232 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 01/30/2003 | US20030022211 Nucleotide sequences coding polypeptide for use in diagnosis and prevention of psychological and nervous system disorders |
| 01/30/2003 | US20030022181 Streptococcus pneumoniae antigens |
| 01/30/2003 | US20030022178 Identification of sortase gene |
| 01/30/2003 | US20030022161 Diagnosing mammary gland cancer in humans; obtain ductal fluid sample, monitor marker gene product expression, amplified concentrations of marker products indicates cancer |
| 01/30/2003 | US20030021858 Mixture of jasmone compound, antioxidant and carnitine |
| 01/30/2003 | US20030021855 Topical applying |
| 01/30/2003 | US20030021846 Sustained release; wet granulation, compaction |
| 01/30/2003 | US20030021843 Antidiabetic preparation for oral administration |
| 01/30/2003 | US20030021816 Antiinflammation agents, antiscarring agent; administering immunosuppressant |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021785 Use of rank antagonists to treat cancer |
| 01/30/2003 | US20030021781 Administering antibodies |
| 01/30/2003 | US20030021779 Immunology response; monoclonal antibodies |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2682251A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | CA2454427A1 A novel g protein-coupled receptor, gave8 |
| 01/30/2003 | CA2454423A1 Method and reagents for identifying gene targets for treating breast cancer |
| 01/30/2003 | CA2454200A1 Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| 01/30/2003 | CA2454189A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 01/30/2003 | CA2454187A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | CA2454185A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | CA2454002A1 Regulator for amount of body fat |
| 01/30/2003 | CA2453977A1 Stents with vitronectin receptor antagonists against restenosis |
| 01/30/2003 | CA2453616A1 Pharmaceutical preparations containing ion exchange resins charged with active ingredients |
| 01/30/2003 | CA2453478A1 Agent for treatment of cerebral ischemic diseases |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2453290A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | CA2453249A1 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/30/2003 | CA2453108A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 01/30/2003 | CA2452832A1 .gamma.-secretase in vitro screening assay |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452518A1 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | CA2443524A1 Methods of profiling gene expression, protein or metabolite levels |
| 01/30/2003 | CA2395992A1 Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and a sh3 domain comprising peptide |
| 01/29/2003 | WO2002009713A2 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/29/2003 | EP1279744A2 Identification and use of molecules implicated in pain |
| 01/29/2003 | EP1279412A2 Pressure-mediated intracellular delivery of molecules of microparticles |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1279402A1 Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules |
| 01/29/2003 | EP1279332A2 Transgenic non-human mammal |